The historic rise of Viagra has long been a example of pharmaceutical success, yet its legacy within the broader sector now triggers questions about long-term gains. Copycat versions are diminishing patent protection , causing concerns that investing in companies significantly dependent to Viagra's once-dominant influence could be a problematic str